Retinal vascular occlusion affects the eye, specifically the retina. The retina is the light-sensitive layer of tissue that lines the back of your eye. It’s covered with special cells called rods and ...

An FDA target action date of August 19, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...

COVID-19 infection may be boosting the numbers of a rare ocular condition in which vision is threatened when veins in the retina are blocked, eye specialists in Southern California report. Risk of ...

Please provide your email address to receive an email when new articles are posted on . Women who filled a prescription for female hormone therapy did not have an increased risk for retinal vein ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

Please provide your email address to receive an email when new articles are posted on . Singer said ANXV (Annexin Pharmaceuticals) is a first-in-class therapy that targets phosphatidylserine and ...

The market battle between Roche’s Vabysmo and Regeneron and Bayer’s Eylea just cranked up a notch. With Vabysmo’s FDA approval to treat retinal vein occlusion (RVO), the rival eye meds share another ...

Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...

Women filling a prescription for female hormone therapy (FHT), and presumably taking FHT, are not at increased risk of retinal artery or retinal vein occlusions. FHT, including oral contraceptive ...